BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 235 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q3 2022. The put-call ratio across all filers is 0.39 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $380,869 | +2.2% | 53,795 | +1.6% | 0.00% | 0.0% |
Q2 2023 | $372,641 | -17.3% | 52,932 | -2.0% | 0.00% | -25.0% |
Q1 2023 | $450,502 | -25.2% | 54,017 | +3.0% | 0.00% | -33.3% |
Q4 2022 | $602,344 | -5.3% | 52,469 | +4.0% | 0.01% | -14.3% |
Q3 2022 | $636,000 | +20.2% | 50,443 | +0.8% | 0.01% | +40.0% |
Q2 2022 | $529,000 | -33.1% | 50,043 | +2.9% | 0.01% | -16.7% |
Q1 2022 | $791,000 | +18.6% | 48,640 | +1.0% | 0.01% | +20.0% |
Q4 2021 | $667,000 | -4.2% | 48,142 | -0.5% | 0.01% | -16.7% |
Q3 2021 | $696,000 | -8.4% | 48,403 | +0.7% | 0.01% | 0.0% |
Q2 2021 | $760,000 | +45.3% | 48,082 | -6.5% | 0.01% | +20.0% |
Q1 2021 | $523,000 | +37.3% | 51,399 | +0.4% | 0.01% | +66.7% |
Q4 2020 | $381,000 | +112.8% | 51,204 | -1.9% | 0.00% | +50.0% |
Q3 2020 | $179,000 | +7.8% | 52,220 | +50.2% | 0.00% | 0.0% |
Q2 2020 | $166,000 | +130.6% | 34,772 | -3.9% | 0.00% | +100.0% |
Q1 2020 | $72,000 | – | 36,168 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
RP Management, LLC | 3,846,154 | $62,538,000 | 25.44% |
ORACLE INVESTMENT MANAGEMENT INC | 1,720,733 | $27,979,000 | 5.53% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 57,000 | $19,282,000 | 4.35% |
MPM BioImpact LLC | 639,089 | $10,392,000 | 2.79% |
Parkman Healthcare Partners LLC | 476,978 | $7,756,000 | 2.27% |
Sarissa Capital Management LP | 1,390,790 | $22,614,000 | 2.14% |
Ghost Tree Capital, LLC | 350,000 | $5,691,000 | 1.24% |
Lisanti Capital Growth, LLC | 662,644 | $10,775,000 | 1.21% |
Baker Brothers Advisors | 12,710,818 | $206,678,000 | 1.19% |
Tamarack Advisers, LP | 125,000 | $2,033,000 | 0.96% |